What SEC filings does Pyxis Oncology, Inc. submit to the SEC?

Pyxis Oncology, Inc. (PYXS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about PYXS?

A Form 4 for PYXS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Pyxis Oncology, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for PYXS?

The 10-K is Pyxis Oncology, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all PYXS SEC filings directly on EDGAR?

You can view all historical Pyxis Oncology, Inc. filings on the SEC EDGAR company page for PYXS. Each filing card on this page links directly to the original SEC document.

How often does Pyxis Oncology, Inc. file with the SEC?

Pyxis Oncology, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling PYXS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

PYXS SEC Filing News — Pyxis Oncology, Inc.

Latest SEC filings for Pyxis Oncology, Inc. (PYXS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monothera…

Sector: Healthcare Industry: Biotechnology Market Cap: $210.2M CIK: 1782223

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Pyxis Oncology, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

PYXS Filing Activity Snapshot 2026-03-25 — 2026-10-02

Insider Transactions (Form 4)

1 buy vs 1 sell

Insider buying and selling activity is balanced in this period.

Largest Form 144 Filing

$107.1K

Dupont Jakob (Director) · 2026-07-02

35,000 shares · Form 4

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Pyxis Oncology, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 7 compensation award, 1 open-market purchase and 1 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market purchase Insider Buying 2026-10-02

PYXS insider GordonMD Global Investments LP (10% Owner) bought 5,517,000 shares

GordonMD Global Investments LP, listed as 10% Owner at Pyxis Oncology, Inc., reported an open-market purchase of 5,517,000 PYXS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	5,517,000	—	—
`P`	Open-market purchase derivative · Common Stock Purchase Warrant	7,546,766	—	—

Filing: Form 4 (Insider Transaction) Insider: GordonMD Global Investments LP (10% Owner) Shares: 5,517,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-08

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Civik Thomas (Director, CEO & Chairman of the Board) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	2,503,050	—	—

Filing: Form 4 (Insider Transaction) Insider: Civik Thomas (Director, CEO & Chairman of the Board)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-20

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Dupont Jakob (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	46,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Dupont Jakob (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Civik Thomas (Director, Interim CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	250,956	—	—

Filing: Form 4 (Insider Transaction) Insider: Civik Thomas (Director, Interim CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

PYXS insider Dupont Jakob (Director) sold 35,000 shares (~$107.1K)

Dupont Jakob, listed as Director at Pyxis Oncology, Inc., reported an open-market sale of 35,000 PYXS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	35,000	$1.60	$56.0K
`S`	Open-market sale	35,000	$3.06	$107.1K
`M`	Option exercise derivative · Stock Option (Right to Buy)	35,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Dupont Jakob (Director) Shares: 35,000 Est. Value: $107.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-25

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Dupont Jakob (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	45,867	—	—

Filing: Form 4 (Insider Transaction) Insider: Dupont Jakob (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-25

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Wadhane Jitendra (Prin Fin & Acct Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	109,461	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	262,635	—	—

Filing: Form 4 (Insider Transaction) Insider: Wadhane Jitendra (Prin Fin & Acct Officer) Shares: 109,461

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-25

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

FLAVIN JOHN L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	45,867	—	—

Filing: Form 4 (Insider Transaction) Insider: FLAVIN JOHN L (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-25

PYXS insider Form 4 filed for equity award, exercise, or tax withholding

Metzger Michael A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	45,867	—	—

Filing: Form 4 (Insider Transaction) Insider: Metzger Michael A (Director)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Pyxis Oncology, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-06-30

PYXS Form 144 filed for proposed insider sale by Dupont Jakob (35,000 shares) ~$107.0K

Dupont Jakob filed a Form 144 with the SEC indicating intent to sell PYXS (Pyxis Oncology, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Dupont Jakob Shares: 35,000 Est. Value: $107.0K

View on SEC EDGAR → Open Filing Document →

Material Events 8 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 8 in this period for Pyxis Oncology, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-01